By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
SCOTTSDALE, Ariz., Jan. 15 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies ...
GAITHERSBURG, Md., Jan. 15 GenVec, Inc. (Nasdaq: GNVC) announced today that 184 events (deaths) have occurred in its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) in patients with locally advanced pancreatic ...
Abbott announces CE Mark (Conformite Europeene) certification for the ARCHITECT human epididymis protein 4 (HE4) test ABBOTT PARK, Ill., Jan. 14 /PRNewswire-FirstCall/ -- A new diagnostic tool, which studies show can aid in determining the ...
EMERYVILLE, Calif., Jan. 14 Bionovo, Inc. (Nasdaq: BNVI) announced today the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer. The results of the study are available online in Breast ...
New technologies offer opportunities to solve mysteries of cancer NEW YORK, Jan. 14 /PRNewswire-USNewswire/ -- The Damon Runyon Cancer Research Foundation announced that three novel approaches to fighting cancer have won 2010 Damon ...
REDWOOD CITY, Calif., Jan. 12 Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of a prospective, multi-center, study that showed the Oncotype DX® breast cancer test Recurrence Score® had a significant impact on ...
OXFORD, England, Jan. 12 A chemotherapy software solution that enables patients to become more involved in managing their own care has been successfully rolled out across a network of hospitals in the UK. The Thames Valley Cancer Network ...
NEW YORK, Jan. 12 Dune Medical Devices today announced the completion of patient enrollment in the MarginProbe(TM) pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of ...
VIENNA, Va., Jan. 11 CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the ...
SAN DIEGO, Jan. 11 bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announced that the company has signed a three-year, exclusive agreement with Ferrer ...
Adding atezolizumab to chemo in stage 3 dMMR colon cancer halves the risk of recurrence, marking a major step in precision cancer therapy.
Biomarkers reveal vital insights that could improve treatment strategies for aggressive prostate cancer, offering hope for better patient outcomes.
A new study reveals how genetics and cancer therapy types together influence the risk of second cancers in childhood cancer survivors.
Exosomes transform prostate cancer care with early detection, tailored treatments, and real-time prognosis tracking for improved patient outcomes.
Researchers have developed a machine learning tool that identifies metabolic markers to help diagnose and monitor colorectal cancer more accurately.
Subscribe to our Free Newsletters!
Medindia's policies are aligned with the United Nations Sustainable Development Goals (SDGs) - SDG 3, SDG 4, SDG 5, SDG 6 , SDG 10 & SDG 12.
Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related condition or disease. Always consult a qualified healthcare professional for medical advice, diagnosis, or treatment. Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers